ACADEMIA
Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
The curtain has risen on generic competition for DPP-4 inhibitors, with copycat versions of Equa (vildagliptin) and Onglyza (saxagliptin) hitting the market on December 6. As more generics are expected from next year, they could have large implications for diabetes…
To read the full story
Related Article
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
ACADEMIA
- Japan Medical Societies Release Tavneos Discontinuation Guidance
November 6, 2026
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





